- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination with Standard of Care Therapy in Patients with Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia (BEXMAB Study)
This study is testing a new drug called bexmarilimab for blood cancers like MDS, CMML, and AML. It aims to see if the drug is safe, what dose is best, and if it helps people get better when used with standard treatments.
For: Chronic Myelomonocytic Leukemia · Myelodysplastic Syndrome · Acute Myeloid LeukemiaFinland - Active not recruitingPHASE1, PHASE2
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
This study looks at a new drug, bexmarilimab, alongside standard treatments for certain blood cancers like leukaemia and MDS. We want to find a safe dose and see how well it works to help patients.
For: Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic SyndromesUnited States · Finland · United Kingdom